MAR
24
2014

NeuMoDx Announces Completion of Series B Financing Funds Product Development for High Throughput Molecular Diagnostic Platform

  Ann Arbor, Michigan (March 26, 2014) – NeuMoDx Molecular, Inc., a privately held diagnostics company developing a new platform for high throughput, low cost molecular testing, today announced completion of its Series B financing. Pfizer Ventures led the $21 million Series
COMMENT Off